STERIS plc (STE) KPIs and segments
Close on Nov 17, 2026Market cap $25.10BP/E 31.5Yield 0.96%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Steris · năm tài chính kết thúc ngày 31 tháng 3
Nhìn nhanh KPI của Steris: 38 chỉ số vận hành, trong đó có Total Capital Equipment Backlog, Remaining Performance Obligations và Constant Currency Organic Growth — Consolidated, lấy từ 137 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Năm tài chính của Steris kết thúc ngày 31 tháng 3 — Q2 FY27 = CQ3 2026 (quý dương lịch).
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q2 FY27 | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Healthcare($M)3 | 1,048 | 1,136 | 1,064 | 1,034 | 975 | 1,057 | 976 | 944 | 901 | 916 | |||
Service revenues($M) | 426 | 423 | 405 | 400 | 389 | 386 | 363 | 353 | 343 | 320 | |||
Consumable revenues($M) | 392 | 376 | 387 | 374 | 359 | 353 | 358 | 342 | 343 | 329 | |||
Capital equipment revenues($M) | 231 | 337 | 272 | 259 | 227 | 318 | 255 | 250 | 215 | 267 | |||
Applied Sterilization Technologies($M)2 | 298 | 289 | 287 | 282 | 281 | 274 | 258 | 257 | 250 | 251 | 235 | ||
Service revenues($M) | 296 | 283 | 276 | 279 | 280 | 258 | 253 | 248 | 249 | 244 | 230 | ||
Capital equipment revenues($M) | 1.40 | 6.10 | 10.2 | 2.10 | 1.60 | 16 | 5 | 8.80 | 1.10 | 6.63 | 5.24 | ||
Life Sciences:($M)3 | 147 | 146 | 145 | 135 | 149 | 136 | 128 | 129 | 161 | 147 | |||
Consumable revenues($M) | 81.5 | 75.9 | 77.2 | 75.3 | 76.1 | 68.7 | 72.1 | 69.8 | 70.4 | 60.1 | |||
Service revenues($M) | 34 | 36.5 | 35.8 | 33.3 | 36.5 | 36.6 | 32.8 | 32.2 | 46.0 | 41.7 | |||
Capital equipment revenues($M) | 31.3 | 33.3 | 31.9 | 26.6 | 36.9 | 31.1 | 23 | 26.5 | 44.2 | 44.8 | |||
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)1 | |||||||||||||
Service($M) | 756 | 743 | 717 | 715 | 701 | 680 | 652 | 633 | 623 | 633 | 591 | ||
Product($M) | 737 | 845 | 779 | 745 | 691 | 801 | 718 | 696 | 656 | 786 | 707 | ||
United States($M) | 1,091 | 1,146 | 1,087 | 1,075 | 1,026 | 1,079 | 1,003 | 980 | 947 | 1,036 | 950 | ||
Other locations($M) | 373 | 382 | 343 | 344 | |||||||||
Other foreign locations($M) | 358 | 343 | 364 | 344 | 327 | 310 | 361 | 328 | |||||
Ireland($M) | 29 | 31.9 | 26.7 | 27.3 | 22.5 | 38.2 | 24.1 | 22.8 | 22.2 | 22.7 | 19.6 | ||
Healthcare($M) | 260 | 283 | 260 | 236 | 280 | 228 | 217 | ||||||
Applied Sterilization Technologies($M) | 143 | 131 | 129 | 128 | 137 | 122 | 116 | 110 | 118 | ||||
Life Sciences:($M) | 61.8 | 61.8 | 59.9 | 58.7 | 58.1 | 52.6 | |||||||
Segment operating income($M) | 343 | 337 | 320 | 295 | 285 | 304 | |||||||
Healthcare($M) | 258 | 260 | 247 | 228 | 217 | 224 | |||||||
Applied Sterilization Technologies($M) | 129 | 128 | 116 | 110 | 118 | 105 | |||||||
Life Sciences:($M) | 61.8 | 59.9 | 58.1 | 53.7 | 52.6 | 56.7 | |||||||
Corporate($M) | -106 | -110 | -101 | -97.1 | -102 | -81.6 | |||||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)1 | |||||||||||||
Healthcare($M) | 459 | 479 | 448 | 442 | 417 | 458 | 424 | 403 | 390 | ||||
Applied Sterilization Technologies($M) | 158 | 147 | 146 | 142 | 151 | 135 | 130 | 123 | 134 | ||||
Life Sciences:($M) | 80.7 | 80.2 | 78.6 | 77.2 | 75.5 | 70.5 | 69.6 | ||||||
Product($M) | 369 | 389 | 361 | 355 | 331 | 368 | 347 | 327 | 316 | 325 | 323 | ||
Service($M) | 315 | 309 | 295 | 291 | 297 | 274 | 264 | 252 | 257 | 258 | 237 | ||
Remaining performance obligations (RPO)($M) | 1,541 | 1,890 | 1,926 | 1,824 | 1,676 | 1,627 | 1,500 | 1,555 | |||||
Total Capital Equipment Backlog($M)2 | 549 | 554 | 491 | 542 | 541 | 515 | 453 | 520 | 481 | 434 | 425 | 534 | |
Healthcare Capital Equipment Backlog($M) | 456 | 444 | 392 | 429 | 428 | 404 | 369 | 435 | 405 | 362 | 354 | 449 | |
Life Sciences Capital Equipment Backlog($M) | 93.4 | 110 | 98.7 | 113 | 114 | 111 | 83.7 | 85.1 | 75.6 | 72.2 | 71.4 | 85 | |
Remaining Performance Obligations (Contracted Pipeline)($M)4 | 1,535 | 1,541 | 1,366 | 1,890 | 1,926 | 1,824 | 1,658 | 1,676 | 1,627 | 1,500 | 1,420 | 1,555 | |
Share Expected to Recognize Within 12 Months(%) | 58.0% | 58.0% | 56.0% | 54.0% | 53.0% | 53.0% | 51.0% | 53.0% | 54.0% | 53.0% | 56.0% | 56.0% | |
Share Expected to Recognize in Years 2–3(%) | 31.0% | 32.0% | 35.0% | 37.0% | 38.0% | 39.0% | 40.0% | 36.0% | 37.0% | 38.0% | 33.0% | 32.0% | |
Current Deferred Service & Maintenance Contract Liabilities($M) | 61.8 | 61.1 | 59.1 | 58.8 | 49.5 | 51.8 | 57.5 | 80 | 72.6 | 69.3 | 70.5 | 90.4 | |
Revenue Recognized from Beginning Deferred Contract Liabilities($M) | 13 | 33.4 | 1 | 9 | 38.5 | 7.40 | 5.60 | 6.10 | 46 | -3.50 | 5.90 | ||
Constant Currency Organic Growth — Consolidated(%)5 | 8.1% | 6.2% | 5.0% | 7.8% | 8.9% | 7.8% | 5.9% | 6.2% | 7.0% | 5.6% | 10.0% | ||
Organic Growth (Excluding M&A)(%) | 8.0% | 6.8% | 7.1% | 9.2% | 9.9% | 8.7% | 5.0% | 6.3% | 7.2% | 5.4% | 11.0% | ||
Reported U.S. GAAP Revenue Growth(%) | 8.8% | 7.3% | 7.3% | 9.2% | 9.9% | 8.7% | 4.3% | 5.6% | 7.3% | 8.1% | 14.8% | ||
Acquisitions Revenue Contribution($M) | 11.3 | 6.90 | 2.40 | 0 | 0 | 0 | 0 | 0 | 11.4 | 41 | 45.3 | ||
Prior-Year Divestitures Revenue Impact($M) | 0 | 0 | 0 | 0 | 0 | 0 | -10 | -7.80 | -8.90 | -7.90 | 0 | ||
Foreign Currency Translation Revenue Impact($M) | -1.10 | 8.40 | 31.5 | 18.4 | 12.7 | 11.8 | -11.7 | 0.40 | 2.10 | -2.90 | 12.4 | ||
Healthcare — Constant Currency Organic Growth(%)4 | 7.4% | 6.4% | 5.7% | 8.2% | 9.0% | 7.6% | 5.6% | 6.5% | 7.1% | 5.2% | 8.5% | 12.4% | |
Healthcare — Organic Growth (Ex-M&A)(%) | 7.5% | 6.9% | 7.2% | 9.0% | 9.5% | 8.2% | 4.9% | 6.5% | 7.2% | 5.1% | 8.8% | 13.2% | |
Healthcare — Reported GAAP Growth(%) | 8.6% | 7.6% | 7.5% | 9.0% | 9.5% | 8.2% | 4.9% | 6.5% | 8.5% | 10.1% | 13.9% | 19.1% | |
Healthcare — Acquisitions Contribution($M) | 11.3 | 6.90 | 2.40 | 0 | 0 | 0 | 0 | 0 | 11.4 | 41 | 45 | 45.3 | |
Healthcare — Foreign Currency Impact($M) | 0.60 | 4.20 | 16.3 | 7.80 | 4.90 | 4.60 | -7.50 | -0.20 | 0.70 | -1.20 | 2.80 | 6.30 | |
Applied Sterilization Technologies (AST) — Constant Currency Organic Growth(%)4 | 5.3% | 4.7% | 1.6% | 7.9% | 7.4% | 10.2% | 10.3% | 9.5% | 8.7% | 7.7% | 4.6% | 4.0% | |
AST — Organic Growth (Ex-M&A)(%) | 5.0% | 5.8% | 5.6% | 11.0% | 9.7% | 12.6% | 9.2% | 9.9% | 9.2% | 7.2% | 4.9% | 5.8% | |
AST — Reported GAAP Growth(%) | 5.0% | 5.8% | 5.6% | 11.0% | 9.7% | 12.6% | 9.2% | 9.9% | 9.2% | 7.2% | 4.9% | 5.8% | |
AST — Acquisitions Contribution($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
AST — Foreign Currency Impact($M) | -1 | 3.20 | 11.1 | 8 | 5.80 | 5.90 | -2.80 | 0.90 | 1.20 | -1.30 | 0.60 | 4 | |
Life Sciences — Constant Currency Organic Growth(%)4 | 18.1% | 7.9% | 6.2% | 5.0% | 11.7% | 4.2% | 0.1% | -1.5% | 3.0% | 4.3% | 1.6% | 19.7% | |
Life Sciences — Organic Growth (Ex-M&A)(%) | 17.7% | 8.6% | 9.0% | 6.9% | 13.3% | 5.2% | -0.8% | -1.7% | 3.0% | 4.0% | 2.0% | 20.9% | |
Life Sciences — Reported GAAP Growth(%) | 17.7% | 8.6% | 9.0% | 6.9% | 13.3% | 5.2% | -6.9% | -6.9% | -3.9% | -2.2% | 2.0% | 20.9% | |
Life Sciences — Acquisitions Contribution($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Life Sciences — Foreign Currency Impact($M) | -0.70 | 0.90 | 4.20 | 2.60 | 2 | 1.30 | -1.30 | -0.30 | 0.10 | -0.40 | 0.70 | 1.40 | |
Total Recurring Stream (Consumables + Service)($M)2 | 1,268 | 1,230 | 1,201 | 1,181 | 1,167 | 1,136 | 1,110 | 1,080 | 1,047 | 1,037 | 1,037 | 981 | |
Consumables($M) | 496 | 474 | 458 | 463 | 452 | 435 | 430 | 428 | 414 | 414 | 404 | 390 | |
Capital Equipment Installations($M) | 321 | 263 | 387 | 316 | 294 | 256 | 371 | 291 | 282 | 242 | 383 | 317 | |
Healthcare — Total Recurring Stream (Consumables + Service)($M) | 852 | 818 | 799 | 792 | 774 | 747 | 739 | 721 | 695 | 687 | 676 | 649 | |
Life Sciences — Total Recurring Stream (Consumables + Service)($M) | 122 | 116 | 119 | 113 | 113 | 109 | 113 | 105 | 105 | 102 | 116 | 102 | |
Geographic Mix — United States Share of Revenue(%)2 | 74.0% | 73.0% | 72.0% | 73.0% | 74.0% | 74.0% | 73.0% | 73.0% | 73.0% | 74.0% | 73.0% | 73.0% | |
International Share of Revenue (Outside U.S. & Ireland)(%) | 24.0% | 25.0% | 26.0% | 26.0% | 24.0% | 24.0% | 25.0% | 25.0% | 25.0% | 24.0% | 25.0% | 25.0% | |
Ireland Share of Revenue(%) | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | |
Full-Year Guidance — Constant Currency Organic Growth (Low)(%)1 | 6.0% | 6.0% | 6.0% | 8.0% | 7.0% | 8.0% | 6.0% | 6.0% | 7.0% | 6.0% | 6.0% | 10.0% | |
Full-Year Guidance — Constant Currency Organic Growth (High)(%) | 7.0% | 7.0% | 7.0% | 8.0% | 8.0% | 8.0% | 6.0% | 6.0% | 7.0% | 6.0% | 7.0% | 10.0% | |
Full-Year Guidance — Adjusted Diluted EPS (Low)($)3 | 11.35 | 11.10 | 11.10 | 10.15 | 10.15 | 9.90 | 9.90 | 9.05 | 9.05 | 9.05 | 9.05 | 8.60 | |
Full-Year Guidance — Adjusted Diluted EPS (High)($) | 11.55 | 11.30 | 11.30 | 10.30 | 10.30 | 10.15 | 10.15 | 9.15 | 9.25 | 9.25 | 9.25 | 8.70 | |
Full-Year Guidance — GAAP Diluted EPS (Low)($) | 8.92 | 8.92 | 9 | 7.97 | 8.04 | 7.79 | 7.82 | 6.66 | 6.70 | 6.70 | 6.55 | 5.35 | |
Full-Year Guidance — GAAP Diluted EPS (High)($) | 9.12 | 9.12 | 9.20 | 8.12 | 8.19 | 8.04 | 8.07 | 6.76 | 6.90 | 6.90 | 6.75 | 5.45 | |
Full-Year Guidance — Free Cash Flow($M)2 | 800 | 800 | 850 | 850 | 850 | 820 | 770 | 700 | 700 | 700 | 700 | 685 | |
Full-Year Guidance — Operating Cash Flow($M) | 1,250 | 1,250 | 1,225 | 1,225 | 1,225 | 1,195 | 1,145 | 1,060 | 1,060 | 1,060 | 1,060 | 995 | |
Full-Year Guidance — Capital Expenditures($M) | 450 | 450 | 375 | 375 | 375 | 375 | 375 | 360 | 360 | 360 | 360 | 310 | |
Adjusted Non-GAAP Diluted EPS (Continuing Operations)($)3 | 2.94 | 2.59 | 2.83 | 2.53 | 2.47 | 2.34 | 2.74 | 2.32 | 2.14 | 2.03 | 2.41 | 2.09 | |
Adjusted Non-GAAP Gross Profit($M) | 720 | 686 | 700 | 657 | 647 | 630 | 657 | 612 | 581 | 577 | 604 | 567 | |
Adjusted Non-GAAP Net Income($M) | 287 | 254 | 278 | 251 | 245 | 232 | 271 | 229 | 213 | 202 | 241 | 208 | |
Adjusted Effective Income Tax Rate(%) | 25.3% | 25.9% | 25.4% | 24.2% | 24.5% | 23.5% | 23.5% | 24.5% | 22.7% | 21.3% | 21.4% | 22.3% | |
Gamma Sterilization Decommissioning — Noncurrent Asset Retirement Obligations (AROs)($M)1 | 14.9 | 14.8 | 14.7 | 14.8 | 14.6 | 14.6 | 13.8 | 13.4 | 13.9 | 13.2 | 13.1 | 13.2 | |
Current Asset Retirement Obligations (AROs)($M) | 0.50 | 0.50 | 0.50 | 0.60 | 0.60 | 0.60 | 0.60 | 0.60 | 0.60 | 0.50 | 0.50 | 0.50 | |
Finished Goods Inventory($M)3 | 427 | 415 | 355 | 384 | 380 | 374 | 335 | 367 | 389 | 372 | 374 | 492 | |
Raw Materials Inventory($M) | 254 | 247 | 225 | 237 | 231 | 223 | 213 | 230 | 236 | 257 | 246 | 304 | |
Work-in-Process Inventory($M) | 95 | 90.1 | 90.7 | 92.9 | 89.6 | 89.5 | 83.1 | 94.3 | 107 | 111 | 98.3 | 118 | |
Inventory Excess & Obsolescence Valuation Reserves($M) | 39.1 | 40.4 | 39.4 | 40.2 | 41.6 | 45.1 | 49.8 | 41.5 | 42.6 | 42.1 | 43.9 | 58 | |
Installed-Base Product Warranty Accrual Balance($M)2 | 14.7 | 15.3 | 17.5 | 17 | 16 | 16.1 | 16.3 | 14.7 | 15 | 14.6 | 15.4 | 15 | |
New Product Warranties Issued($M) | 3.90 | 2.30 | 5.70 | 5.50 | 4.80 | 4.90 | 4.30 | 5 | 3.50 | 4.30 | |||
Warranty Claim Settlements & Repairs($M) | 4.60 | 4.40 | 5.30 | 4.40 | 5 | 5.10 | 4.50 | 4.60 | 4.30 | 3.40 | |||
Ethylene Oxide (EO) & Legal Contingencies Accrual($M)2 | 0 | 43.2 | 43.2 | 43.2 | 43.2 | 43.2 | 48.2 | 0 | |||||
Restructuring Accrual Balance($M) | 8.90 | 4.60 | 7.10 | 10.8 | 13.1 | 16.2 | 18.4 | 17.7 | 21.8 | 21.4 | 0.70 | ||
Accounts Receivable Allowance for Doubtful Accounts($M) | 31.8 | 29.9 | 27.3 | 29.1 | 27.1 | 25.6 | 24.4 | 22.4 | 24.5 | 23.7 | 23 | 28 | |
Total Statutory Employee Compensation & Benefit Costs2 | |||||||||||||
Current Accrued Employee Compensation Liabilities($M) | 157 | 153 | 221 | 188 | 168 | 155 | 193 | 161 | 147 | 149 | 165 | 179 | |
Unrecognized Share-Based Compensation Expense($M) | 67 | 85.9 | 42.6 | 54.6 | 70.1 | 88.4 | 51.1 | 60.4 | 75.9 | 94 | 60.1 | 68.7 | |
FDA 510(k) Premarket Clearances — STERIS & Acquired Subsidiaries3 | 0 | 4 | 0 | 0 | 1 | 5 | 3 | 5 | 2 | 4 | 5 | 9 | |
U.S. Medical Device Industry — Total FDA 510(k) Clearances | 856 | 923 | 756 | 806 | 797 | 886 | 736 | 856 | 767 | 793 | 713 | 877 | |
FDA Medical Device Recall Events — STERIS & Subsidiaries (All Classes) | 0 | 3 | 1 | 2 | 2 | 0 | 0 | 0 | 4 | 0 | 3 | 1 | |
FDA Recall Enforcement Reports — STERIS & Subsidiaries | 0 | 3 | 1 | 2 | 2 | 0 | 0 | 0 | 4 | 0 | 4 | 0 | |
FDA MAUDE Adverse Event Reports (MDRs) — STERIS Devices4 | 161 | 159 | 147 | 145 | 152 | 153 | 139 | 134 | 116 | 83 | 100 | 134 | |
MAUDE Device Malfunction Reports — STERIS | 103 | 158 | 145 | 143 | 150 | 152 | 136 | 131 | 115 | 82 | 99 | 132 | |
MAUDE Patient Injury Reports — STERIS | 58 | 1 | 2 | 2 | 2 | 1 | 3 | 3 | 1 | 1 | 0 | 1 | |
MAUDE Death Reports — STERIS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
U.S. Medical Device Industry — Total MAUDE MDR Reports | 1,189,695 | 923,529 | 811,618 | 751,012 | 819,444 | 632,296 | 685,251 | 709,498 | 699,798 | 631,546 | 586,309 | 573,619 | |
U.S. Federal Contract Obligations Awarded to STERIS($M) | 95.8 | 92.5 | 668 | 40.0 | 183 | 31.0 | 138 | 26.3 | 109 | 29.8 | 36.7 | 28.4 | |
U.S. PPI — Surgical Appliance & Supplies Manufacturing (NAICS 339113, Index)1 | |||||||||||||
U.S. Hospital Industry Total Quarterly Revenue (Census QSS)($M) | 47,896 | 46,674 | 46,834 | 46,295 | 45,370 | 45,358 | 45,284 | 43,778 | 43,505 | 43,709 | 43,264 | ||
Consolidated Revenue($M)5 | 1,589 | 1,493 | 1,588 | 1,496 | 1,460 | 1,391 | 1,481 | 1,371 | 1,329 | 1,280 | 1,419 | 1,298 | |
Gross Profit($M) | 711 | 684 | 697 | 656 | 646 | 628 | 641 | 610 | 579 | 572 | 583 | 560 | |
Operating Income (GAAP)($M) | 294 | 286 | 317 | 273 | 266 | 246 | 216 | 245 | 220 | 186 | 220 | 227 | |
Research & Development Expense($M) | 31.5 | 28.6 | 28.8 | 29.5 | 28.2 | 26.4 | 27.6 | 27.4 | 27 | 25.6 | 27.5 | 25.3 | |
Selling, General & Administrative Expense($M) | 366 | 370 | 352 | 352 | 350 | 354 | 334 | 336 | 329 | 336 | 309 | 308 | |
Net Income Attributable to Shareholders($M) | 214 | 200 | 220 | 193 | 192 | 177 | 146 | 174 | 150 | 145 | -1.40 | 141 | |
Operating Cash Flow($M)1 | 289 | 367 | 335 | 298 | 288 | 420 | 261 | 333 | 251 | 304 | 255 | 291 | |
Capital Expenditures($M) | 76.1 | 87.5 | 90.2 | 98.7 | 86.5 | 93.6 | 70.9 | 89.2 | 102 | 108 | 91.5 | 119 | |
Total Assets($M)7 | 10,714 | 10,736 | 10,737 | 10,591 | 10,411 | 10,405 | 10,147 | 10,008 | 10,242 | 10,109 | 11,064 | 11,435 | |
Cash & Cash Equivalents($M) | 531 | 482 | 440 | 424 | 319 | 280 | 172 | 155 | 172 | 198 | 207 | 196 | |
Inventories, Net($M) | 737 | 712 | 632 | 674 | 659 | 641 | 581 | 650 | 689 | 699 | 675 | 856 | |
Property, Plant & Equipment, Net($M) | 2,188 | 2,172 | 2,161 | 2,133 | 2,092 | 2,055 | 1,957 | 1,922 | 1,930 | 1,834 | 1,765 | 1,845 | |
Goodwill($M) | 4,179 | 4,189 | 4,195 | 4,232 | 4,215 | 4,223 | 4,096 | 4,044 | 4,151 | 4,057 | 4,071 | 4,112 | |
Acquired Intangible Assets, Net($M) | 1,497 | 1,564 | 1,620 | 1,692 | 1,749 | 1,817 | 1,854 | 1,923 | 2,004 | 2,049 | 2,119 | 2,987 | |
Long-Term Indebtedness($M) | 1,650 | 1,650 | 1,813 | 1,898 | 1,897 | 1,903 | 1,919 | 2,039 | 2,156 | 2,236 | 3,120 | 3,231 | |
Total Shareholders' Equity($M) | 7,257 | 7,207 | 7,184 | 7,155 | 7,009 | 6,957 | 6,603 | 6,416 | 6,594 | 6,355 | 6,302 | 6,415 | |
13 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- STERIS plc operates on a fiscal year ending March 31 (for example, FY2026 ended March 31, 2026; Q1 FY2027 ended June 30, 2026; Q2 FY2027 ended September 30, 2026).
- Primary operational metrics focus on: (1) Capital Equipment Backlog ($548.9M at Q2 FY2027 across Healthcare and Life Sciences) and multi-year Remaining Performance Obligations ($1,535.0M); (2) Constant Currency Organic Growth and M&A/FX revenue bridges across Consolidated, Healthcare, Applied Sterilization Technologies (AST), and Life Sciences; and (3) the installed-base Recurring revenue model (Consumables + Sterilization/Maintenance Service vs. Capital Equipment) across consolidated operations and each segment.
- All growth rates, shares, non-GAAP reconciliations, and segment figures are directly reported by STERIS plc; no ratios, margins, sums, or growth rates are computed. The only derived cells are cumulative period splits from year-to-date cash flow and footnote tables (Q4 = full year − nine months; quarterly = year-to-date − prior year-to-date). Prior-period continuing-operations figures reflect STERIS's retrospective reclassification of the divested Dental segment as discontinued operations.
Không hiện vì thiếu các kỳ gần đây (9)
- Global AST Sterilization Facility Count ('over 60 owned or leased facilities' in Form 10-K Item 2) — excluded because management reports only an open-ended lower bound rather than a point count
- Countries with Operating Locations ('more than 35 other countries' in Form 10-K Item 2) — excluded because disclosed only as an open-ended bound
- Global Year-End Headcount in Form 10-K FY2022–FY2024 ('over 16,000' / 'just over 17,000') — excluded as bound phrasing; exact statutory average employee counts by segment (17,937 in FY2026) are included instead
- STERIS Solutions Limited UK Carbon Reduction Plan GHG Emissions (PPN 06/21) — excluded because a FY2024 organizational boundary recalculation broke comparability with FY2023 (Scope 1 changed from 576.5 tCO2e to 16.1 tCO2e), leaving only 2 comparable years (FY2024–FY2025) under the revised boundary
- STERIS Instrument Management Services Limited & Synergy Health Sterilisation UK Limited PPN 06/21 Carbon Reduction Plans — excluded because only single-year FY2024 submissions were publicly available (<3 consecutive periods)
- Employee Pulse Engagement Survey Participation Rate (88% in FY2025, 87% in FY2026) — excluded because the global pulse survey launched in FY2025 with only 2 annual observations (<3 periods)
- Dental Segment Revenue, Operating Income & Headcount — excluded from continuing series following the divestiture of the Dental business in Q1 FY2025
- Quarterly Price Realization (in basis points) & Gross Tariff Cost Impact ($M) — mentioned selectively in earnings call remarks starting FY2026 without a continuous multi-year quarterly series
- FDA Premarket Approvals (PMA) for STERIS — zero PMA filings across recent periods because STERIS's sterilization and surgical products are cleared via the 510(k) pathway
Dữ liệu cập nhật 2026-11-14.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Capital Equipment Backlog & Contracted Service Pipeline (Key #1)
Constant Currency Organic Growth & M&A Bridge (Key #2)
Installed-Base Recurring Mix & Segment Revenue Model (Key #3)
- Total Recurring Stream (Consumables + Service) ($M)35 kỳ
- Healthcare — Total Recurring Stream (Consumables + Service) ($M)24 kỳ
- AST — Contract Sterilization & Laboratory Testing Service ($M)19 kỳ
- Life Sciences — Total Recurring Stream (Consumables + Service) ($M)34 kỳ
- Geographic Mix — United States Share of Revenue (%)35 kỳ
Full-Year Management Outlook & Non-GAAP Operating Performance
Sterilization Operations, Cobalt-60 AROs, Inventory Stages, Warranty & IP
- Gamma Sterilization Decommissioning — Noncurrent Asset Retirement Obligations (AROs) ($M)32 kỳ
- Finished Goods Inventory ($M)32 kỳ
- Installed-Base Product Warranty Accrual Balance ($M)33 kỳ
- Ethylene Oxide (EO) & Legal Contingencies Accrual ($M)8 kỳ
- Minimum Supplier Purchase Commitments (Raw Materials & Components) ($M)8 kỳ
- Property, Plant & Equipment Depreciation Expense ($M)10 kỳ
- United States Patents Held8 kỳ
Workforce by Segment, Safety, GHG Emissions & Supply Chain
- Total Global Employees (Average, Continuing Operations)7 kỳ
- Total Statutory Employee Compensation & Benefit Costs ($M)7 kỳ
- CEO-to-Median Employee Pay Ratio (×)8 kỳ
- OSHA Total Recordable Incident Rate (TRIR, per 100 FTE)5 kỳ
- Global Scope 1 Direct GHG Emissions (Metric Tons CO2e)3 kỳ
- Verified 3TG Smelters & Refiners in Supply Chain7 kỳ
Synergy Health UK Operating Subsidiaries — Statutory Workforce Disclosures
External Regulatory Clearances, Federal Contracts & Industry Benchmarks
- FDA 510(k) Premarket Clearances — STERIS & Acquired Subsidiaries118 kỳ
- FDA MAUDE Adverse Event Reports (MDRs) — STERIS Devices118 kỳ
- U.S. Federal Contract Obligations Awarded to STERIS ($M)118 kỳ
- Cumulative Clinical Trials Sponsored — STERIS & Subsidiaries11 kỳ
- U.S. PPI — Surgical Appliance & Supplies Manufacturing (NAICS 339113, Index)130 kỳ
Consolidated Financial Context
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Steris
- STERIS plc Form 8-K Earnings Release (Exhibit 99.1), filed 2026-11-04 ↗
- STERIS plc Form 8-K Earnings Release (Exhibit 99.1), filed 2026-05-11 ↗
- STERIS plc Form 10-K, filed 2026-05-29 ↗
- STERIS plc Form 10-Q, filed 2026-11-05 ↗
- openFDA 510(k) Clearances Database (STERIS, Medivators, Cantel, US Endoscopy) ↗
- openFDA MAUDE Medical Device Reporting Database ↗
- USAspending.gov Federal Prime Contract Awards (STERIS) ↗
- STERIS plc Form 10-Q, filed 2026-11-05 ↗
- STERIS plc Form 10-K, filed 2026-05-29 ↗
- UK Government Equalities Office — Statutory Gender Pay Gap Service (2025 Snapshot) ↗
- STERIS plc Definitive Proxy Statement (DEF 14A), filed 2026-06-11 ↗
- STERIS plc FY2026 Corporate Responsibility Fact Sheet ↗
See a number that looks wrong?